NANOBIOTIX Announces First Patient Injected In New Phase 1/2 Study Evaluating Radiotherapy-Activated NBTXR3 Plus Anti-PD-1 For Patients With Advanced Cancers
Portfolio Pulse from Bill Haddad
Nanobiotix has announced the first patient injection in a new Phase 1/2 study evaluating the combination of radiotherapy-activated NBTXR3 and anti-PD-1 for patients with advanced cancers.
July 19, 2023 | 8:16 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Nanobiotix's announcement of the first patient injection in a new Phase 1/2 study could potentially boost investor confidence in the company's research and development capabilities.
The initiation of a new Phase 1/2 study indicates progress in Nanobiotix's research and development efforts. This could potentially lead to positive investor sentiment, driving the stock price up in the short term.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100